1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Checkpoint Inhibitors for Treating Cancer: Market Report with Forecasts 2016-2026 : Revealing Potentials of CTLA-4 and PD-1 Inhibitor Drugs and R&D

Checkpoint Inhibitors for Cancer – Explore Sales Potentials of that Rising Market

Are you interested in the future of cancer drugs? Our new analysis forecasts revenues for checkpoint inhibitors. Visiongain’s report gives those predictions to 2026 at overall world market, submarket, product and national level.

Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and revenues those emerging cancer therapies can achieve. There you also explore trends, results, R&D and opportunities, seeing commercial prospects.

Read on, please, to explore the industry for checkpoint inhibitor cancer therapies and see what future revenue that expanding pharmaceuticals market could generate.

Predictions and other analysis to benefit your research, assessments, plans and decisions
The future looks promising for checkpoint inhibitors. New products enter that market and drug candidates reach clinical trials. Discover, from 2016, what revenues and other progress are possible in that emerging, expanding market.

Besides sales forecasting to 2026, our work shows recent results, growth rates and market shares. There you find original analysis. Also assess research and development. You gain 61 tables, 34 charts and two interviews with companies.

Our study’s purpose is to help your research, analyses and decisions on cancer therapies using that emerging drug class. Our work also benefits your authority and reputation for commercial insight, helping you compete and succeed.

The following sections show how our new investigation benefits your work.

Forecasts covering the overall world market and segments for checkpoint inhibitors

Discover in our new analysis revenue predictions to 2026 for checkpoint inhibitor submarkets at overall world level, for cancer therapy, and by therapeutic class:

- CTLA-4 Inhibitors
- PD-1 Inhibitors
- Products in development – the R&D pipeline.

Where lie the best prospects? You assess outlooks for revenue expansion, seeing where you can gain. You also investigate competitors’ actions and outlooks.

That way you hear where needs and business opportunities exist. With a rising incidence of cancers, the demand for better treatment rises, giving pharma companies vast opportunities.

Discover what is possible. You also find sales forecasts by individual drug.

Predictions of products’ sales – what is possible for those cancer-treating drugs?

How will checkpoint inhibitor medicines perform from 2015 to 2026 at world level? Our study forecasts revenues of these brands:

- Yervoy (ipilimumab)
- Opdivo (nivolumab)
- Keytruda (pembrolizumab).

There you find how products can compete and succeed. That way you investigate trends, exploring challenges, changes and opportunities.

Discover what the future holds for checkpoint inhibitors and their developers, producers and marketers. Our work also shows you geographical sales predictions.

National markets – what outlooks for those anticancer drug revenues?
Advances in biopharma expand the range and use of checkpoint inhibitors. Our study shows you individual revenue forecasts to 2026 for seven national and two regional markets:
- United States
- Japan
- Germany, France, United Kingdom, Italy and Spain (EU5)
- European Union market overall
- APAC region, grouped prediction

That way you assess countries and regions with highest revenues and potential sales growth. See what is possible in developed and developing countries.

Our study also explores developments for novel and improved cancer treatments.

R&D for those anticancer medicines – trends, innovations and progress

Our work assesses checkpoint inhibitor R&D in oncology. Profiles appear for 19 drug candidates, with revenue forecasts to 2026 for four agents:

- Atezolizumab (MPDL3280A, Roche)
- Durvalumab (MEDI4736, AstraZeneca/MedImmune)
- Avelumab (MSB0010718C, Merck KGaA/Pfizer)
- Tremelimumab (CP-675,206, AstraZeneca).

That way you examine technological advances, seeing progress in clinical trials.

Our report’s author said: “We expect that market to continue its rise, changing cancer therapy. Those drugs have already made strides in melanoma and NSCLC (non-small cell lung cancer) treatment.

“Checkpoint inhibitors harness the body’s immune system to attack cancerous cells, also using immune memory cells to eliminate relapses.”

Discover in our investigation what is possible. That R&D gains momentum from rising cancer prevalence and other forces raising demand for those emerging therapies.

Events and changes affecting companies treating cancer via checkpoint inhibitors

Explore other issues, including these forces shaping that industry and market:

- Mechanisms and advantages of checkpoint inhibition
- Pricing of treatments and effects of those costs on healthcare payers
- Side effects and regulatory issues, including disadvantages of the therapies
- Biomarkers paving the way for optimum utility
- LAG-3 inhibitors – an emerging field of checkpoint inhibitor research
- Combination therapies – their benefits and promise
- Competition – see how crowded that market could become.

You also gain SWOT analysis, assessing what stimulates and restrains that expanding anti-cancer drugs market.

That way you see what is possible for leading pharma companies and specialists in biological drugs and related therapies. Why miss out? Instead explore what the future holds for checkpoint inhibitors in oncology.

Leading organisations and overall 2020 market value – what revenues are possible?
Our work predicts the world market for those drugs will reach $16.55bn in 2020. That market will multiply in revenues many times from 2016 to 2026. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.

That way you assess what organisations hold most potential. Those companies include Bristol-Myers Squibb, Merck & Co., Roche, AstraZeneca and Pfizer.

Our study also shows you interviews with Innate Pharma and Prima Biomed. Discover what the future holds for participants in that industry, exploring what they say and do, as well as their potentials.

7 ways Checkpoint Inhibitors for Treating Cancer: Market Report with Forecasts 2016-2026 helps you

Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge:

- Revenues for anti-cancer checkpoint inhibitors to 2026 – assess scope for investments, developments, production and marketing
- Submarket revenues to 2026 covering 3 therapeutic segments – explore treatment categories, seeing their sales outlooks from 2015
- Existing and expected products’ sales to 2026 – discover predicted revenues of 7 drugs, seeing how those medicines can compete and succeed
- National market forecasting to 2026 for leading countries – explore the best regions for treatment demand, sales and revenue expansion
- R&D – see progress, trends and prospects in that oncological research and development, finding technological, clinical and commercial possibilities
- Companies, news and opinions – examine participants in that rising market, gaining insight to help you stay ahead, succeed and benefit your authority
- Analysis of what stimulates and restrains that market – assess challenges and strengths, helping you compete and gain advantages.

Table Of Contents

Checkpoint Inhibitors for Treating Cancer: Market Report with Forecasts 2016-2026 : Revealing Potentials of CTLA-4 and PD-1 Inhibitor Drugs and RandD
1. Report Overview
1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2015
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to the Checkpoint Inhibitor Anti-Cancer World Market 2015
2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
2.2 Checkpoint Inhibitor Drug Treatments in Oncology

3. Leading Checkpoint Inhibitors: Anti-Cancer Drug Forecasts 2016-2026 and Leading Companies in the World Market
3.1 Leading Checkpoint Inhibitor Anti-Cancer Drug Treatments on the Market in 2015
3.1.1 Yervoy (ipilimumab) - Bristol-Myers Squibb
3.1.1.1 Yervoy: Sales Analysis
3.1.2 Opdivo (nivolumab) - Bristol-Myers Squibb/Ono Pharmaceutical
3.1.2.1 Opdivo: Sales Analysis
3.1.3 Keytruda (pembrolizumab) - Merck and Co.
3.1.3.1 Keytruda: Sales Analysis
3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Market in 2015
3.2.1 Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment: World Market 2016-2026
4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2014
4.2 The World Anti-Cancer Checkpoint Inhibitor Market: Revenue Forecasts 2015-2026
4.3 Leading Checkpoint Inhibitor Treatment Submarkets Forecast 2016-2026
4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2016-2026
4.3.2 The PD-1 Inhibitors Submarket Forecast 2016-2026
4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
4.3.4 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Market
4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
5.1 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatments Market 2014-2015
5.2 World Checkpoint Inhibitor Anti-Cancer Treatment Market: Regional Forecast 2016-2026
5.2.1 How Will Regional Market Shares Change to 2026?
5.3 The US Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4 The EU Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.5 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.6 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026

6. The Checkpoint Inhibitor Anti-Cancer Treatment Market Pipeline Analysis 2016-2026
6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
6.1.1 Atezolizumab (MPDL3280A/RG7446) - Roche/Genentech
6.1.2 Durvalumab (MEDI4736) - AstraZeneca/MedImmune
6.1.3 Avelumab - (MSB0010718C) - Merck KGaA/Pfizer
6.1.4 Pidilizumab (CT-011) - CureTech Ltd
6.1.5 AMP-224 - GSK/Amplimmune
6.1.6 TSR-042 - TESARO Bio/AnaptysBio
6.1.7 AMP-514 (MEDI0680) - AstraZeneca/MedImmune
6.1.8 REGN2810 - Regeneron/Sanofi
6.2 CTLA-4 Inhibitors
6.2.1 Tremelimumab (CP-675,206) - AstraZeneca
6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
6.3.1 IMP321- Prima Biomed
6.3.2 BMS-986016 - Bristol-Myers Squibb
6.3.3 IMP701 - Prima BioMed/Novartis
6.4 KIR Inhibitors
6.4.1 Lirilumab (IPH2102/BMS-986015) - Innate Pharma/Bristol-Myers Squibb
6.5 Anti-NKG2A Inhibitors
6.5.1 IPH2201 - Innate Pharma/AstraZeneca/MedImmune
6.6 Other Checkpoint Inhibitors
6.6.1 VISTA Inhibitors
6.6.1.1 CA-170 - Curis/Aurigene
6.6.2 IDO and TDO Inhibitors
6.6.2.1 Indoximod (NLG-9189) - NewLink Genetics
6.6.2.2 NLG919 - NewLink Genetics
6.6.2.3 INCB024360 - Incyte/Roche
6.6.3 A2aR Inhibitors
6.6.3.1 HTL-1071 - AstraZeneca/Heptares
6.6.4 Future Areas of Pipeline Research

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
7.2 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.2.1 A Novel Treatment Method that Harnesses the Immune System's Vast Potential
7.2.2 Pricing of the Treatments Will Attract Companies
7.2.3 Cost of Treatment Will Restrain Market Access
7.2.4 Side Effects May Prohibit Growth
7.3 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.3.1 Biomarkers Pave the Way for Optimum Utility
7.3.2 Combination Therapies Are Achieving Superior Results
7.3.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
7.3.4 Crowding of the Market With Similar Products

8. Research Interviews
8.1 Interview with Dr Nicolai Wagtmann, PhD, Chief Scientific Officer, Innate Pharma, Marseille, France
8.1.1 Innate Pharma's Immunotherapy Portfolio
8.1.2 The Advantages and Mechanisms Used by Checkpoint Inhibitors
8.1.3 The Disadvantages of Checkpoint Inhibitors
8.2 Interview with Dr. Frederic Triebel, CFO/CSO of Prima Biomed, Founder of Immutep
8.2.1 LAG-3 Inhibitors: An Upcoming Area of Checkpoint Inhibitor Research
8.2.2 Advantages and Disadvantages of LAG-3 Inhibitors on the Checkpoint Inhibitor Market
8.2.3 The Future Direction of the Checkpoint Inhibitor Market for Prima Biomed

9. Conclusions
9.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Market: Current World Outlook
9.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Market to 2026
9.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026: The US and EU Will Retain Their Lead
9.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Market

List of Tables

Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2015
Table 3.1 Yervoy (Ipilimumab): Historical Sales ($m, AGR%), 2011-2014
Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.8 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2014
Table 3.9 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2015
Table 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2014
Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2014
Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2015
Table 4.4 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2015-2020
Table 4.5 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2021-2026
Table 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2015
Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2015-2020
Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2021-2026
Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2015-2020
Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2021-2026
Table 4.11 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2015-2020
Table 4.12 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2021-2026
Table 4.13 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market, 2015-2026
Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Sizes ($bn), Market Shares (%), 2014
Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2015-2020
Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2021-2026
Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2014-2019
Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2020-2026
Table 5.6 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.7 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.8 EU5 Market Shares (%), 2014-2019
Table 5.9 EU5 Market Shares (%), 2020-2026
Table 5.10 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.11 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.12 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.13 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.14 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.15 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.16 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.17 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.18 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.19 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.24 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.25 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.1 Selected Combination Therapies for Atezolizumab, 2015
Table 6.2 Atezolizumab Forecast: Revenue ($bn), 2016-2020
Table 6.3 Atezolizumab Forecast: Revenue ($bn), 2021-2026
Table 6.4 Durvalumab Forecast: Revenue ($bn), 2016-2020
Table 6.5 Durvalumab Forecast: Revenue ($bn), 2021-2026
Table 6.6 Avelumab Forecast: Revenue ($bn), 2017-2020
Table 6.7 Avelumab Forecast: Revenue ($bn), 2021-2026
Table 6.8 Tremelimumab Forecast: Revenue ($bn), 2016-2020
Table 6.9 Tremelimumab Forecast: Revenue ($bn), 2021-2026
Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Cancer Treatment Market, 2015
Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Cancer Treatment Market, 2015
Table 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2016, 2020, and 2026
Table 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2016, 2020, and 2026

List of Figures

Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Market Segmentation Overview, 2015
Figure 3.1 Yervoy (ipilimumab): Historical Sales ($m, AGR%), 2011-2014
Figure 3.2 Yervoy Forecast, Revenue ($bn), 2015-2026
Figure 3.3 Opdivo Forecast, Revenue ($bn), 2015-2026
Figure 3.4 Keytruda Forecast, Revenue ($bn), 2015-2026
Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2014
Figure 3.6 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2015
Figure 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2014
Figure 4.2 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), 2015-2026
Figure 4.3 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2015
Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2015-2026
Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2015-2026
Figure 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2020
Figure 4.7 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2026
Figure 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Shares (%), 2014
Figure 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), 2014-2025
Figure 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2020
Figure 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2026
Figure 5.5 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.6 EU Market for the Checkpoint Inhibitor Cancer Treatment by Leading Country (%), 2014
Figure 5.7 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market, Market Sizes ($bn), 2014-2025
Figure 5.8 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.9 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.10 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.11 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.12 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.13 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.14 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 6.1 Atezolizumab Forecast: Revenue ($bn), 2016-2026
Figure 6.2 Durvalumab Forecast: Revenue ($bn), 2016-2026
Figure 6.3 Avelumab Forecast: Revenue ($bn), 2017-2026
Figure 6.4 Tremelimumab Forecast: Revenue ($bn), 2016-2026
Figure 9.1 Checkpoint Inhibitor Anti-Cancer Drug Treatment Market Forecast by Class: Market Sizes ($bn), 2014, 2016, 2020, and 2026
Figure 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2014, 2016, 2020, and 2026

Companies Listed
AbbVie
Agilent Technologies
American Cancer Society
Amgen
Amplimmune
AnaptysBio
ASCO (American Society of Clinical Oncology)
AstraZeneca
Aurigene Discovery Technologies
Bristol-Myers Squibb
Celgene
CHMP (Committee for Medicinal Products for Human Use)
Commission de la Transparence
CoStim Pharmaceuticals
CRI (Cancer Research Institute)
CureTech Ltd
Curis Inc
Daiichi Sankyo
Dako (subsidiary of Agilent Technologies)
DMC (Data Monitoring Committee)
DNAtrix
Dynavax
Eddingpharm
EMA (European Medicines Agency)
European Organisation for Research and Treatment and Cancer (EORTC)
FDA (US Food and Drug Administration)
French National Authority for Health
GlaxoSmithKline (GSK)
Heptares
IGR (Institut Gustav Roussy)
Immutep
Incyte
Innate Pharma
INSERM
iTeos Therapeutics
JandJ
LICR (Ludwig Cancer Research)
Medarex
MedImmune
Medivation Inc
Merck and Co.
Merck KGaA
MHLW (Ministry of Health, Labour, and Welfare)
MHRA (Medicines and Healthcare Products Regulatory Agency)
Mirati Therapeutics
NEC Corporation
NewLink Genetics
NHS (National Health Service)
NICE (the National Institute for Health and Care Excellence)
Novartis
Novo Nordisk
Ono Pharmaceutical
Paris University
Pfizer
Pharmacyclics
Plexxikon (subsidiary of Daiichi Sankyo)
Prima Biomed
QIMR Berghofer Medical Research Institute
Regeneron
Roche
Sanofi
Sosei Group Corporation
Syndax
TESARO Inc
Teva Pharmaceutical Industries
The de Duve Institute
WHO (World Health Organization)
Yamaguchi University

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.